Assessing cortisol levels in non-classical congenital adrenal hyperplasia: focus on the V281L variant
Therapeutic Advances in Endocrinology and Metabolism · 2025-10 · 16
DOI: 10.1177/20420188251388397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Endocrinology and Metabolism, online erschienen am 27.10.2025. Verfasst von Meliha Esra Bilici und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology, Zonguldak Bulent Ecevit University School of Medicine, B Block, 1st Floor, Esenköy, Kozlu, Zonguldak 67600, Tu…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Recent guidelines about Non-classical Congenital Adrenal Hyperplasia (NCCAH) indicate that if the peak cortisol response to the adrenocorticotropic hormone (ACTH) stimulation test is 10 ng/dL and had been investigated for 11 common CYP21A2 mutations. A peak cortisol response below 18 µg/dL was insufficient for our polyclonal assay. The cases were divided into two groups: Inadequate/low cortisol response group (LCR; n : 11) and adequate/normal response group ( n : 25). We correlated biallelic genotype and cortisol response. Genotypes were classified as mild/mild (M/M), mild/severe (M/S), and heterozygous on a single allele based on the genotype’s effect on enzyme activity. P30L, V281L, P453S, and R339H are mild NCCAH mutations, whereas Q318X, R356W, exon 6 cluster mutations, Intron2A, and 8 bp deletions were severe. All cohorts with the V281L variant were separated into three groups (M/M, M/S, mild/undefined) and evaluated separately.
Results
Almost one-third of patients had inadequate cortisol reserve. In the LCR group, 17-OHP 0’ levels were greater, but cortisol 0’ levels were lower, with no difference in stimulated responses (15.4 ± 10.5 vs 7.8 ± 6.2, p : 0.016 for basal 17-OHP; 40.7 ± 48.6 vs 32.3 ± 26.4, p : 0.63 for stimulated 17-OHP). The 17-OHP cutoff values were found to be 4.2 and 30.4 ng/dL, with 100% specificity for both groups. In 36% of the LCR group, mild–mild mutations were found. ACTH, cortisol (0’ and peak), and 17-OHP (0’ and peak) levels were similar in mild/mild and mild/severe groups. The V281L mutation was present in 86.1% of our cohort, with inadequate cortisol response in 29% of cases with V281L mutation. Differences were observed between the 0’ and peak cortisol levels in the V281L groups, with post hoc analysis indicating a difference between one allele heterozygous (mild/undefined) and mild/severe group.
Conclusion
Our findings emphasize that a significant portion of patients with the mild/mild V281 mutation exhibit inadequate cortisol responses, highlighting the importance of the ACTH stimulation test in diagnosis and the need for careful monitoring in clinical treatment, as well as consideration of genotype variations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Endocrinology, Zonguldak Bulent Ecevit University School of Medicine, B Block, 1st Floor, Esenköy, Kozlu, Zonguldak 67600, Turkey.
- Department of Pediatric Endocrinology, Ankara University School of Medicine, Cebeci, Ankara, Turkey.
ORCID-Profile: Meliha Esra Bilici
Zitieren
APA
Bilici, M. E., Şıklar, Z., Özsu, E., Aycan, Z., Uyanık, R., Ceran, A., & Berberoğlu, M. (2025). Assessing cortisol levels in non-classical congenital adrenal hyperplasia: focus on the V281L variant. Therapeutic Advances in Endocrinology and Metabolism, 16. https://doi.org/10.1177/20420188251388397
Vancouver
Bilici ME, Şıklar Z, Özsu E, Aycan Z, Uyanık R, Ceran A, et al. Assessing cortisol levels in non-classical congenital adrenal hyperplasia: focus on the V281L variant. Therapeutic Advances in Endocrinology and Metabolism. 2025;16. doi:10.1177/20420188251388397
BibTeX
@article{Bilici2025,
author = {Bilici, Meliha Esra and Şıklar, Zeynep and Özsu, Elif and Aycan, Zehra and Uyanık, Rukiye and Ceran, Ayşegül and Berberoğlu, Merih},
title = {Assessing cortisol levels in non-classical congenital adrenal hyperplasia: focus on the V281L variant},
journal = {Therapeutic Advances in Endocrinology and Metabolism},
year = {2025},
volume = {16},
doi = {10.1177/20420188251388397}
}
EUVIMED